Wall Street’s Key Stock Analysts Research Report, All Buys

Wall Street’s Key Stock Analysts Research Report, All Buys

#buys #WallStreet #analysts #research #reports #hold #sell #trade #avoid

$AMBA $BLKB $CIDM $HXL $NLS $SGMO $PCVX

These are all Buys if you can manage the risk.

Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. These reports cover stocks to buy

Below is our list for Wednesday, 8 July, as follows:

Ambarella Inc. (NASDAQ:AMBA) was raised to Buy from Underperform with a 55 price target at Needham.

Blackbaud Inc. (NASDAQ:BLKB):This tech stock has a solid earnings history and has seen estimates for the full year start to tick higher. Shares most recently closed at 58.38 and have a consensus price target of 53.60

Cinedigm Corp. (NASDAQ:CIDM) was started as Buy with a 3.50 price target at Benchmark.

Hexcel Corp. (NYSE:HXL) was started with a Buy rating and a 52 price target at Seaport Global.

Nautilus Inc. (NYSE:NLS) was reiterated as Buy and its price target was raised to 12 at SunTrust Robinson Humphrey.

Nvidia Corp. (NASDAQ:NVDA) was reiterated as Buy and its price objective was raised to 460 from 420 at BofA Securities. Shares closed at 393.57 ahead of this call and has a 388.20 consensus target price.

Sangamo Therapeutics Inc. (NASDAQ:SGMO) was started with a Buy rating and a 22 price target at SunTrust Robinson Humphrey.

Vaxcyte Inc. (NASDAQ:PCVX) was started as Buy with a 40 price target at Needham. The 52-wk trading range is 17.80 – 36.50

Have a healthy day, Keep the Faith!

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he it the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.